Kidney patients with a very limited residual kidney function usually receive hemodialysis treatment. The problem is that the currently used technique is not able to clear the blood from all toxins. Especially the toxins with a large molecular weight and toxins bound to proteins cannot be removed. Because these toxins remain in the blood, the patients’ health and well-being are (increasingly) impaired. Relitech has invented and patented a method that can improve this: adjunctive blood detoxification (ABD).
In the ABD, toxins are selectively captured by aptamers. Aptamers are short strands of DNA or RNA that specifically bind the toxin of interest. In this way, toxins that usually remain in the blood after hemodialysis will be removed by the ABD, positioned in the blood flow leaving the hemodialysis device. We are currently working on a proof-of-concept in the MIND project .
This project was initiated by Relitech and we collaborate with partners in various fields: biochemists at the University of Bonn worked on aptamer selection, medical doctors from the university hospital in Gent advised on toxins and worked on user requirements, chemists from Surfix work on the binding of the aptamers on the substrate and biochemists from Febotec work on sensor techniques to measure the toxin levels in blood. We are co-creators and whatever field you are in: we can be your partner.